Literature DB >> 33620588

Turning the spotlight on the oligosaccharide chain of GM1 ganglioside.

Elena Chiricozzi1, Erika Di Biase2, Giulia Lunghi2, Maria Fazzari2, Nicoletta Loberto2, Massimo Aureli2, Laura Mauri2, Sandro Sonnino3.   

Abstract

It is well over a century that glycosphingolipids are matter of interest in different fields of research. The hydrophilic oligosaccharide and the lipid moiety, the ceramide, both or separately have been considered in different moments as the crucial portion of the molecule, responsible for the role played by the glycosphingolipids associated to the plasma-membranes or to any other subcellular fraction. Glycosphingolipids are a family of compounds characterized by thousands of structures differing in both the oligosaccharide and the ceramide moieties, but among them, the nervous system monosialylated glycosphingolipid GM1, belonging to the group of gangliosides, has gained particular attention by a multitude of Scientists. In recent years, a series of studies have been conducted on the functional roles played by the hydrophilic part of GM1, its oligosaccharide, that we have named "OligoGM1". These studies allowed to shed new light on the mechanisms underlying the properties of GM1 defining the role of the OligoGM1 in determining precise interactions with membrane proteins instrumental for the neuronal functions, leaving to the ceramide the role of correctly positioning the GM1 in the membrane crucial for the oligosaccharide-protein interactions. In this review we aim to report the recent studies on the cascade of events modulated by OligoGM1, as the bioactive portion of GM1, to support neuronal differentiation and trophism together with preclinical studies on its potential to modify the progression of Parkinson's disease.

Entities:  

Keywords:  Drug development; GM1 oligosaccharide; Neurodegeneration; Neurodifferentiation; Neuroprotection; Parkinson’s disease

Mesh:

Substances:

Year:  2021        PMID: 33620588      PMCID: PMC7917043          DOI: 10.1007/s10719-021-09974-y

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  102 in total

1.  Genetic engineering of Escherichia coli for the economical production of sialylated oligosaccharides.

Authors:  Nicolas Fierfort; Eric Samain
Journal:  J Biotechnol       Date:  2008-03-10       Impact factor: 3.307

2.  A new procedure for the extraction, purification and fractionation of brain gangliosides.

Authors:  G Tettamanti; F Bonali; S Marchesini; V Zambotti
Journal:  Biochim Biophys Acta       Date:  1973-01-19

3.  Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.

Authors:  Gusheng Wu; Zi-Hua Lu; Joon Ho Seo; Samar K Alselehdar; Shawn DeFrees; Robert W Ledeen
Journal:  Exp Neurol       Date:  2020-03-09       Impact factor: 5.330

Review 4.  The mechanism of protein kinase C activation.

Authors:  K P Huang
Journal:  Trends Neurosci       Date:  1989-11       Impact factor: 13.837

Review 5.  Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders.

Authors:  Marco Piccinini; Federica Scandroglio; Simona Prioni; Barbara Buccinnà; Nicoletta Loberto; Massimo Aureli; Vanna Chigorno; Elisa Lupino; Giovanni DeMarco; Annarosa Lomartire; Maria Teresa Rinaudo; Sandro Sonnino; Alessandro Prinetti
Journal:  Mol Neurobiol       Date:  2010-02-03       Impact factor: 5.590

Review 6.  GM1 Ganglioside: Past Studies and Future Potential.

Authors:  Massimo Aureli; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Gino Toffano; Cynthia Secchieri; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2015-03-12       Impact factor: 5.590

7.  Micellar properties of glycosphingolipids in aqueous media.

Authors:  B Ulrich-Bott; H Wiegandt
Journal:  J Lipid Res       Date:  1984-11       Impact factor: 5.922

8.  Ganglioside GM1 binds to the Trk protein and regulates receptor function.

Authors:  T Mutoh; A Tokuda; T Miyadai; M Hamaguchi; N Fujiki
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  [Trials of monosialoganglioside (Sygen) treatment in ischemic stroke].

Authors:  M Wender; J Mularek; A Godlewski; J Losy; G Michałowska-Wender; M Sniatała-Kamasa; M Wójcicka
Journal:  Neurol Neurochir Pol       Date:  1993 Jan-Feb       Impact factor: 1.621

10.  Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1+/- mouse model.

Authors:  Elena Chiricozzi; Laura Mauri; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Margherita Maggioni; Manuela Valsecchi; Simona Prioni; Nicoletta Loberto; Diego Yuri Pomè; Maria Grazia Ciampa; Pamela Fato; Gianluca Verlengia; Stefano Cattaneo; Robert Assini; Gusheng Wu; Samar Alselehdar; Robert W Ledeen; Sandro Sonnino
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

View more
  8 in total

Review 1.  Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.

Authors:  Inka Brockhausen; John Schutzbach; Jiabei Wang; Beth Fishwick; Jennifer Brockhausen
Journal:  Glycoconj J       Date:  2021-11-10       Impact factor: 2.916

2.  Treatment effects of monosialotetrahexosylganglioside on severe traumatic brain injury in adults.

Authors:  Hanqing Chu; Jindan Gao
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

3.  Gangliosides and Cell Surface Ganglioside Metabolic Enzymes in the Nervous System.

Authors:  Massimo Aureli; Laura Mauri; Emma Veronica Carsana; Dorina Dobi; Silvia Breviario; Giulia Lunghi; Sandro Sonnino
Journal:  Adv Neurobiol       Date:  2023

Review 4.  A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.

Authors:  J S Schneider
Journal:  Glycoconj J       Date:  2021-05-26       Impact factor: 2.916

Review 5.  Glycans in autophagy, endocytosis and lysosomal functions.

Authors:  Fulvio Reggiori; Hans-Joachim Gabius; Massimo Aureli; Winfried Römer; Sandro Sonnino; Eeva-Liisa Eskelinen
Journal:  Glycoconj J       Date:  2021-08-14       Impact factor: 2.916

6.  Plasma membrane glycosphingolipid signaling: a turning point.

Authors:  Elena Chiricozzi
Journal:  Glycoconj J       Date:  2021-08-16       Impact factor: 2.916

7.  β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration.

Authors:  Giulia Lunghi; Emma Veronica Carsana; Nicoletta Loberto; Laura Cioccarelli; Simona Prioni; Laura Mauri; Rosaria Bassi; Stefano Duga; Letizia Straniero; Rosanna Asselta; Giulia Soldà; Alessio Di Fonzo; Emanuele Frattini; Manuela Magni; Nara Liessi; Andrea Armirotti; Elena Ferrari; Maura Samarani; Massimo Aureli
Journal:  Cells       Date:  2022-07-29       Impact factor: 7.666

Review 8.  Novel insights on GM1 and Parkinson's disease: A critical review.

Authors:  Maria Fazzari; Erika Di Biase; Giulia Lunghi; Laura Mauri; Elena Chiricozzi; Sandro Sonnino
Journal:  Glycoconj J       Date:  2022-01-22       Impact factor: 2.916

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.